201 related articles for article (PubMed ID: 22763305)
1. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
Aksu K; Kurt E
Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
[No Abstract] [Full Text] [Related]
2. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
[No Abstract] [Full Text] [Related]
3. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
[No Abstract] [Full Text] [Related]
6. Basophil activation test: do not lose control.
Maietta G
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):36-7. PubMed ID: 25781191
[No Abstract] [Full Text] [Related]
7. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab.
Phillips-Angles E; Barranco P; Lluch-Bernal M; Dominguez-Ortega J; López-Carrasco V; Quirce S
J Allergy Clin Immunol Pract; 2017; 5(3):842-845. PubMed ID: 28117272
[No Abstract] [Full Text] [Related]
8. Summaries for patients. Omalizumab therapy for patients with severe asthma.
Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
[No Abstract] [Full Text] [Related]
9. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
10. Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations.
Chanez P
Eur Respir J; 2001 Aug; 18(2):249-50. PubMed ID: 11529279
[No Abstract] [Full Text] [Related]
11. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
13. Potential benefit of omalizumab in respiratory diseases.
Bonini M; Di Maria G; Paggiaro P; Rossi A; Senna G; Triggiani M; Canonica GW
Ann Allergy Asthma Immunol; 2014 Nov; 113(5):513-9. PubMed ID: 25442695
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma.
Thomson NC
Evid Based Med; 2014 Aug; 19(4):135. PubMed ID: 24627175
[No Abstract] [Full Text] [Related]
15. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
Lang DM
Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
[No Abstract] [Full Text] [Related]
16. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
17. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
18. Echinococcus multilocularis infection in a patient treated with omalizumab.
Skiepko R; Zietkowski Z; Skiepko U; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
J Investig Allergol Clin Immunol; 2013; 23(3):199-200. PubMed ID: 23967760
[No Abstract] [Full Text] [Related]
19. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
Di Stefano F; Cinti B; Antonicelli L
Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
